{"id":"blu-808","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"24%","effect":"Nausea"},{"rate":"21%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BLU-808 selectively targets and inhibits the KIT receptor tyrosine kinase, which is involved in the pathogenesis of various cancers.","oneSentence":"BLU-808 is a potent and selective KIT inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:25:12.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastrointestinal stromal tumor (GIST)"}]},"trialDetails":[{"nctId":"NCT06931405","phase":"PHASE2","title":"Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2025-05-28","conditions":"Chronic Inducible Urticaria, Chronic Spontaneous Urticaria","enrollment":105},{"nctId":"NCT06922448","phase":"PHASE2","title":"Study of BLU-808 in Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Blueprint Medicines Corporation","startDate":"2025-04-14","conditions":"Allergic Rhinoconjunctivitis","enrollment":21},{"nctId":"NCT06948032","phase":"PHASE1","title":"Study of BLU-808 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Blueprint Medicines Corporation","startDate":"2024-08-07","conditions":"Healthy Participants","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BLU-808","genericName":"BLU-808","companyName":"Blueprint Medicines Corporation","companyId":"blueprint-medicines-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BLU-808 is a potent and selective KIT inhibitor. Used for Gastrointestinal stromal tumor (GIST).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}